



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : G01N 33/532, 33/533, 33/58</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/18437</p> <p>(43) International Publication Date: 15 April 1999 (15.04.99)</p>
<p>(21) International Application Number: PCT/US98/20831</p> <p>(22) International Filing Date: 1 October 1998 (01.10.98)</p> <p>(30) Priority Data: 08/943,491 3 October 1997 (03.10.97) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/943,491 (CIP) Filed on 3 October 1997 (03.10.97)</p> <p>(71) Applicant (for all designated States except US): BECTON DICKINSON AND COMPANY [US/US]; 1 Becton Drive, Franklin Lakes, NJ 07414 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): DAVIS, Kenneth, A. [US/US]; 321 Blakewood Way, Box 25, Woodside, CA 94062 (US). BISHOP, James, A. [US/US]; 319 Brook Avenue, Santa Cruz, CA 95062 (US). ABRAMS, Barnaby [US/US]; 301 Molton Avenue, San Carlos, CA 94070 (US).</p>		<p>(74) Agent: REITER, Stephen, E.; Gray Cary Ware & Freidenrich, Suite 1600, 4365 Executive Drive, San Diego, CA 92121 (US).</p> <p>(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: CHROMOPHORES IN THE PREPARATION OF NOVEL TANDEM CONJUGATES</p> <p>(57) Abstract</p> <p>The inventors herein disclose new heterobifunctional chromophores that are capable of coupling with two distinct moieties. One moiety may be either a signal-enhancing agent or a blocking agent. The second moiety may be one member of a specific binding pair. The invention is based in part on the surprising result that when a chromophore is used as a "cross-linker" between a signal-enhancing agent and a member of a binding pair (essentially being buried between the two), the signal of the chromophore is not quenched. This arrangement, wherein the chromophore acts simultaneously as a cross-linker and a detectable compound, provides significant advantages over previously known compounds since the chromophore is sterically hindered from interacting non-specifically with substances present in the test systems. Moreover, the chromophore can be used as a cross-linker with little or no loss of detectable signal.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CHROMOPHORES IN THE PREPARATION OF NOVEL TANDEM CONJUGATES

FIELD OF THE INVENTION

The present invention relates to novel bifunctional chromophores useful for labeling materials such as proteins or cells, novel complexes containing bifunctional
5 chromophores, and methods of using them.

BACKGROUND OF THE INVENTION

Fluorescent labeling reagents have become increasingly useful investigative tools. The wider use of fluorescently labeled probes has resulted partly from advances in instrumentation and partly from the availability of new and improved
10 fluorescent dyes. The cyanine dyes have received particular interest since relatively minor alterations in their chemical structure allows for variation in their excitation and emission wavelengths, an advantage for designing multicolor systems useful for simultaneous detection of more than one fluorescent probe.

More recently the cyanine dyes have become widely used as one
15 component of a tandem conjugate with a second fluor, often proteinaceous fluorophores such as phycoerythrin (PE) or Peridinin-chlorophyll a-protein (PerCP). When the emission spectrum of one fluor overlaps the excitation spectrum of another, and they are sufficiently close to each other (<10 nm), it is possible for the excitation energy of the first fluor to be transferred to the second through a fluorescent resonance energy transfer
20 process (Glazer and Stryer, Biophys J. 43:383-386, 1983).

A significant drawback to the use of these reagents, particularly for labeling antibodies used in analysis and sorting of blood cells, is the tendency for the fluor complex to bind to components of the system in an indiscriminate manner (van

Vugt, et al, Blood 88:2358-2359, 1996; Beavis and Pennline, Cytometry 24:390-394, 1996; Shapiro, Practical Flow Cytometry, 3rd ed, pg 282, 1995).

A need, therefore, still exists for new labeling reagents that are sensitive, easily detected, and exhibit little or no undesirable fluor-mediated binding.

5

BRIEF DESCRIPTION OF THE INVENTION

The inventors herein disclose new heterobifunctional chromophores that are capable of coupling with two distinct moieties. One moiety may be either a signal-enhancing agent or a blocking agent. The second moiety may be one member of a specific binding pair. The invention is based in part on the surprising result that when a
10 chromophore is used as a "cross-linker" between a signal-enhancing agent and a member of a binding pair (essentially being buried between the two), the signal of the chromophore is not quenched. This arrangement, wherein the chromophore acts simultaneously as a cross-linker and a detectable compound, provides significant advantages over previously known compounds since the chromophore is sterically
15 hindered from interacting non-specifically with substances present in the analytical system. Moreover, the chromophore can be used as a cross-linker with little or no loss of detectable signal.

Also disclosed are complexes formed between a bifunctional chromophore and a signal-enhancing agent. The signal-enhancing agent is capable of
20 participating in resonance energy transfer reactions. The interaction between the chromophore and the signal-enhancing agent may be covalent or non-covalent. Alternatively, the bifunctional chromophore may form a complex with a blocking agent.

Invention complexes can be used in assays involving non-covalent binding to the complementary member of the specific binding pair. Thus, the present
25 invention should find widespread application since a wide variety of methods involve competitive or non-competitive binding of one member of a binding pair to another for detection, analysis or measurement of the presence of the complementary member of the binding pair.

Similar chromophore complexes known in the art have been widely used but exhibit significant drawbacks including relative dimness (making them unsuitable for detection of complementary binding pair members present at low levels), photobleaching, signal spillover into neighboring detection channels (a critical problem when detecting multiple colors simultaneously), instability, and non-specific binding to irrelevant or inappropriate components of the analytical system. The chromophore and methods of the invention, however, overcome these problems, particularly the problem of non-specific binding.

Also disclosed are methods of making the heterobifunctional chromophores of the invention and methods for making novel complexes having bifunctional chromophores as one of their components. The complexes are suitable for a variety of uses such as the labeling of antibodies for use as immunologic reagents and the labeling of DNA for use as a probe. Tandem complexes available in the art do not employ bifunctional chromophores, wherein the chromophore is buried between the signal enhancing agent and the member of the specific binding pair (Waggoner, et al, EP 747 700, published 12/11/96; Stryer, et al, US Patent No. 4,542,105, issued 9/17/85).

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 schematically illustrates the manner in which the conjugates of the invention interact with one component of a binding pair, in this illustration, an antibody. Previously, dye conjugates (e.g., PE-Cy5, PerCP-Cy5.5, APC-Cy7) were bound to the antibody via a cross-linking moiety on the signal-enhancing agent leaving the dye (e.g., Cy5, Cy5.5, Cy7) exposed to its surroundings so that it could interact with vessel walls, cell surfaces, etc. In the conjugates of the invention, the chromophore is bifunctionalized so that it functions both as a detectable dye compound and a crosslinking moiety attaching the chromophore:signal-enhancer complex to the antibody (effectively "burying" the chromophore and blocking its ability to bind non-specifically).

Figure 2 compares fluorescent staining of whole blood with CD3-PerCP, the prior art CD3-PerCP-Cy5.5 (Cy5.5 "exposed"), and CD3-Cy5.5-PerCP (Cy5.5

“buried”) of the invention (See Example 2). CD3 antibody labeled with Mal/Cy5.5-PerCP complex of the invention more effectively differentiates T-lymphocyte populations from other white blood cell populations with lower background than CD3 antibody labeled with Mal/PerCP-Cy5.5 of the prior art. The latter shows strong
5 chromophore (Cy5.5)-mediated binding to monocytes.

Figure 3 compares the chromophore-specific binding to monocytes of CD3-PerCP, CD3-PerCP-Cy5.5 (Cy5.5 “exposed”) and CD3-Cy5.5-PerCP (Cy5.5 “buried”) (See Example 2). The dot plots of side scatter vs F13 (A-1, B-1 and C-1) show gating of T-lymphocytes and monocytes, which are displayed as an FL3 histogram of
10 PerCP/PerCP-Cy5.5 intensity (A-2, B-2 and C-2). CD3 antibody labeled with Mal/Cy5.5-PerCP complex of the invention shows little or no chromophore-specific binding to monocytes.

DETAILED DESCRIPTION OF THE INVENTION

The invention herein discloses heterobifunctionalized chromophores,
15 wherein one functionality on said chromophore is capable of coupling with a signal-enhancing agent or a blocking agent, and the other functionality is capable of coupling with a member of a specific binding pair.

By “heterobifunctional” it is meant that the chromophore has two different functional groups, each of which is capable of forming a linkage with a second
20 molecule. Suitable examples of functional groups include succinimidyl esters, isothiocyanates, carbodiimide activated carboxyls, hydrazide activated aldehyde imidoesters, maleimides, vinyl sulfones, active halogens, pyridyldisulfides, thiols, and the like.

By “chromophore” it is meant a compound capable of being detected
25 colorimetrically or fluorometrically. The specific examples disclosed herein describe chromophores detected by fluorescence. It should be understood, however, that the compounds and methods described can equally be utilized with chromophores that are

detected by other means readily available to those skilled in the art, such as, for example absorbance or phosphorescence.

Chromophores contemplated for use in the practice of the present invention are detectable compounds having two functional groups, each of which is capable of undergoing a chemical reaction with a second compound such that the chromophore and second compound undergo a chemical interaction. When the two functional groups are the same, the chromophore is referred to herein as “homobifunctional”, whereas when the two functional groups are different, the chromophore is referred to herein as “heterobifunctional” (as defined above). In an alternate embodiment of the invention, a monofunctional chromophore can be modified with a trifunctional linker, thereby introducing two available sites of attachment where only one previously existed. The chromophore may be a fluorescent dye, a non-fluorescent dye, or the like. Examples of suitable chromophores include, but are not limited to, fluorescein and its derivatives and the cyanine dyes such as isothiocyanines, merocyanines, indocarbocyanines (e.g., Cy3), benzindocarbocyanines (e.g., Cy3.5), indodicarbocyanines (e.g., Cy5), benzindodicarbocyanines (e.g., Cy5.5), indotricarbocyanines (e.g., Cy7), benzindotricarbocyanines (e.g., Cy7.5), thiazole orange, oxazole yellow, CYA (3-(epsilon-carboxy-pentyl)-3'ethyl-5,5'-dimethyloxacarbo-cyanine), and the like (see, for example, Mujumdar, et al *Bioconjugate Chem.* 4(2):105-111, 1993; Ernst, et al, *Cytometry* 10:3-10, 1989; Mujumdar, et al, *Cytometry* 10:11-19, 1989; Southwick, et al, *Cytometry* 11:418-430, 1990; Hung, et al, *Anal. Biochem.* 243(1):15-27, 1996; *Nucleic Acids Res.* 20(11):2803-2812, 1992; Mujumdar, et al, *Bioconjugate Chem.* 7:356-362, 1996; and Southwick and Waggoner, US Patent No. 4,981,977, issued January 1, 1991, incorporated by reference herein in its entirety).

Cyanine dyes are the presently preferred chromophores for use in the practice of the present invention. Particularly preferred cyanine dyes are the indodicarbocyanines and the indotricarbocyanines. Synthesis of these dyes is described in detail in Mujumdar, et al, *Bioconjugate Chem.* 7:356-362, 1996 and Southwick, et al,

Cytometry 11:418-430, 1990. A particularly preferred chromophore is Cy5.5-Bis-OSu (compound X (Cy5.205.OSu) in Mujumdar, 1996, supra). This dye contains two succinimidyl ester reactive groups which can be readily derivatized as described herein. It is understood by those skilled in the art that bifunctional chromophores contemplated for use in the practice of the present invention can be homobifunctional (and thus useful as intermediates for the preparation of heterobifunctional chromophores and/or for the preparation of novel complexes as described herein) or heterobifunctional. Thus, such chromophores can be isolated or synthesized so as to contain two identical reactive groups, one of which can be subsequently modified to create heterofunctionality, if desired. Alternatively the heterobifunctional chromophore can be initially synthesized with different reactive groups.

The chromophores of the invention can be coupled to either a signal-enhancing agent or a blocking agent. By "signal-enhancing agent" it is meant a compound that is capable of forming a complex with the bifunctional chromophore and is additionally capable of emitting a detectable signal, for example, a fluorescent signal.

A suitable signal-enhancing agent, in the case of fluorescing compounds, will be capable of participating in fluorescent resonance energy transfer (FRET) reactions, (see, Glazer and Stryer, *Biophys. J.* 43:383-386, 1983). In FRET reactions, a donor molecule becomes excited at a wavelength A and emits radiation at a wavelength B. An acceptor molecule is subsequently excited by the radiation emitted from the donor molecule (wavelength B) and emits at a wavelength C. A fluorescent signal-enhancing molecule useful in the invention can act as either donor molecule or acceptor molecule.

Examples of signal-enhancing agents contemplated for use in the practice of the present invention include, but are not limited to, small organic molecules such as fluorescein and its derivatives, Texas red, rhodamine, umbelliferone, lanthanide chelates, dipyrrometheneboron difluoride, Rhodol green, proteinaceous fluorophores such as the phycobiliproteins (phycoerythrin (PE), allophycocyanin (APC)), Peridinin-chlorophyll-proteins (PerCP), yellow fluorescent proteins (YFPs), green fluorescent proteins (GFPs), and the like, (see Daubner, et al, *PNAS* 84(24):8912-8916, 1987; Prasher, et al, *Gene*

111(2):229-233, 1992; Recktenwald, US Patent 4,876,190, issued 10/24/89, and publications cited therein; Stryer, et al, US Patent No. 4,520,110, issued 5/28/85; Selvin, et al, US Patent No. 5,622,821, issued 4/22/97).

A particularly preferred signal-enhancing agent is PerCP, which can be
5 isolated from a variety of phytoplankton species. This proteinaceous fluorophore contains a wide range of functional groups for conjugation including amino, and carboxyl groups. PerCP and its isolation is described in detail in Recktenwald, US Patent No. 4,876,190, issued 10/24/89, incorporated by reference herein in its entirety. While PerCP itself has some utility as a fluorescent dye, its lack of sensitivity (relative
10 dimness) and its tendency to rapidly bleach when used with a strong laser limit its applicability. The invention complexes are significantly brighter than PerCP alone. For example, the heterobifunctional chromophore-PerCP complex used in the Examples below is approximately five times as bright as PerCP used alone. In addition, this complex does not photobleach under conditions where PerCP alone is photobleached,
15 allowing the complex to be useful in such applications as stream-in-air flow cytometers and fluorescent cells sorters, which generally use stronger lasers.

The chromophores of the invention may alternatively be coupled to a blocking agent. By "blocking agent" it is meant a compound that is capable of forming a complex with a bifunctional chromophore but which is generally unreactive with other
20 substances once the complex is formed. A preferred blocking agent will be capable of reducing the ability of the chromophore to participate in chromophore-mediated undesirable binding. The interaction between the chromophore and the blocking agent may be covalent or non-covalent. A signal-enhancing agent may also be a blocking agent.

25 Suitable blocking agents are relatively large molecules that are relatively inert. Well known examples of blocking agents used in the art include, but are not limited to, serum proteins such as serum albumins (such as bovine serum albumin) and alpha and gamma globulins; milk proteins such as casein and cellulose; biocompatible

polymers such as polyalkylene glycols; and the like. Particularly preferred blocking agents are the polyalkylene oxides (e.g., polyethylene glycols (PEGs)).

PEGs are polyether diols of the general structure $\text{HO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2-\text{OH}$. Their desirability as a blocking agent derives from, among other things, their wide range of solubilities in both aqueous and organic media, their relative lack of toxicity and immunogenicity, their nonbiodegradability and their relative inertness once derivatized. They are commercially available in a variety of molecular weights, typically between 1000 and 20,000 Daltons. One of skill in the art would easily be able to select the appropriate size of PEG molecule for use as a blocking agent with the chromophores employed in accordance with the present invention. Monomethyl PEG (mPEG) is often used to prepare conjugates since the presence of only one derivatizable end group on mPEG minimizes crosslinking and improves the homogeneity of PEG-conjugate preparations. A review of functionalized PEGs for the preparation of conjugates can be found in Zalipsky, *Bioconjugate Chem.* 6:150-165, 1995.

The chromophore of the invention is additionally able to couple with a member of a specific binding pair. By "specific binding pair" it is meant a pair of molecules that specifically interact with one another in preference to interaction with any other molecule. The specificity of binding between two molecules can also be judged by the strength of their interaction with one another. Binding pairs are said to exhibit specific binding when they exhibit avidity of at least 10^7 , preferably at least 10^8 , more preferably at least 10^9 liters/mole. One example of a specific binding pair is an antibody and antigen.

A member of a binding pair suitable for conjugation with a chromophore complex of the invention will comprise at least one functional group(s) capable of coupling to a functional group of a bifunctionalized chromophore with up to 10 or higher being possible. Examples of functional groups include amino, thio, carboxyl, and the like. Binding pairs can include, for example without limitation, antibodies and antigens or haptens, nucleotides (which specifically bind to complementary oligonucleotides when oligomerized), biotin and avidin or streptavidin, ligands and receptors, and the like.

The chromophore complex may be coupled to either member of the binding pair as would be appropriate for the intended use of the labeled conjugate.

The chromophores of the invention can couple with a signal-enhancing agent or blocking reagent and member of a binding pair by covalent or non-covalent
5 means. Non-covalent means include electrostatic means, hydrogen bonding, and the like.

Depending on the molecules employed for the preparation of conjugated complexes according to the invention, a wide variety of linking groups may be used for coupling by covalent interactions, both for linking the chromophore to the signal-enhancing agent or blocking agent and linking the chromophore to the member of the
10 binding pair. Suitable functional groups for the bifunctionalized chromophore include, but are not limited to, succinimidyl, isothiocyanate, carbodiimide activated carboxyl, hydrazide activated aldehyde imidoester, and the like, all of which react with amino groups; and maleimide, vinyl sulfone, active halogen, pyridyldisulfide, and the like, all of which react with sulfhydryl; and so on. General discussions of covalent cross-linking
15 using reagents having different functional groups can be found in Han et al, Int. J. Biochem 16(2):129-145, 1984 and Feeney, Int. J. Peptide Protein Res. 29:145-161, 1987. Methods of attaching chromophores to oligonucleotides via a linking spacer can be found in Linn, et al, US Patent No. 5,597,696, issued 1/28/97, incorporated by reference herein in its entirety.

20 The utility of the chromophores and complexes of the invention is readily recognized by those skilled in the art. The chromophore complexes can be used to label antibodies (polyclonal or monoclonal) which are then useful in a variety of methodologies including fluorescent activated cell sorting or analysis, immunoassays, immunostaining, and the like. Antibody conjugates can also be used for diagnostic
25 purposes, both *in vitro* and *in vivo*. Ballou, et al, for example, describe a method of using antibody conjugates for the detection of tumors *in vivo*. (Ballou, et al, Cancer Immunol. Immunother. 41(4):257-263, 1995) Lanza, et al, describe an *in vitro* method of

diagnosing leukemia using antibody conjugates. (Lanza, et al, Leuk Lymphoma 18 (Supp 1):25-30, 1995).

Non-antibody proteins can also be labeled with the chromophore complexes disclosed herein. For example, antigens may be coupled with a chromophore complex and used in competitive immunoassays. Protein ligands such as growth factors or cytokines can be labeled with chromophore complexes and subsequently used to study ligand:receptor interactions for either research or clinical purposes.

The complexes of the invention can be used to label a variety of non-protein molecules. Chen and Evangelista, for example, describe a multianalyte drug assay wherein labeled morphine and phencyclidine (PCP) are used in a competitive immunoassay to detect drug levels in urine (Chen and Evangelista, Clin. Chem. 40(9):1819-1822, 1994).

Nucleotides or oligonucleotides can be labeled using the chromophore complexes disclosed herein. Individual nucleotide conjugates can be subsequently incorporated into oligonucleotides by nick translation or polymerase chain reaction (PCR) (Zhu, et al, Nucleic Acids Res. 22(16):3418-3422, 1994). Alternatively, oligonucleotides can be directly conjugated with the chromophore complexes (Zheng, et al, Anal. Biochem 231(1):256-260, 1995). The resulting labeled oligonucleotides (by either method) are useful in both research and clinical applications including DNA and RNA hybridization-based diagnostic methods, DNA and RNA sequencing, restriction fragment mapping, fluorescence *in situ* hybridization (FISH), and the like, (see, for example, Zeng, et al, supra; Yu, et al, Nucleic Acids Res. 22(15):3226-3232, 1994; Hung, et al, Anal Biochem 243(1):15-27, 1996).

The complexes of the invention can be included as reagents in kits (either as starting materials (heterobifunctionalized chromophore and signal-enhancing agent) or pre-formed complexes prepared from homobifunctional or heterobifunctional chromophores) provided for use in, for example, the methodologies described above.

The invention is described in greater detail by reference to the following non-limiting examples.

Example 1 - Synthesis of Cy5.5-PerCP employing a heterobifunctional chromophore

- 5 Twelve volumes of the chromophore Cy5.5-Bis-OSu Reactive Dye (OSu/Cy5.5/OSu) (Amersham Life Science, Cat. No. R15500: 33 mM in dimethyl formamide (DMF)), were added to 8 volumes of DMF, 76 volumes of buffer (20 mM morpholinoethane sulfonic acid (MES), 1 mM ethylene diamine tetraacetic acid (EDTA), pH 7.0), and 4 volumes of 100 mM mercaptoethylamine-HCl (Aldrich Cat. No. 12,292-
10 0). After a 20 minute incubation at room temperature, 9 volumes of 500 mM bis-maleimidotriethylene glycol (Molecular BioSciences Cat. No. 46777) in DMF were added and incubation continued a further 20 minutes at room temperature. The reaction mixture containing the heterobifunctional Cy5.5 (Mal/Cy5.5/OSu) and other reaction products was stored on ice if to be used immediately or at -80° C for longer term storage.
- 15 PerCP, 50 nmoles (1.8 mg, QuantaPhy, Inc.) in 50 mM Na phosphate, 1 mM EDTA pH 8.0 was incubated with 100 nmoles of Mal/Cy5.5/OSu for 30 minutes at room temperature. These conditions were selected to minimize the number of PerCP molecules containing two chromophore molecules. The amino groups of PerCP react with the remaining succinimidyl ester moiety (OSu) of the Mal/Cy5.5/OSu. The
20 Mal/Cy5.5-PerCP complex was separated from free Mal/Cy5.5/OSu and other reaction products by buffer exchange into a buffer containing 0.14 M Na acetate (pH 5.5) and 1 mM EDTA using Sephadex™ G-50. The ratio of Cy5.5 to PerCP was determined by absorption at 280, 478 and 674 nm and found to be 0.6:1.

- An antibody specific to T-lymphocytes (CD3(Leu4) Becton Dickinson
25 Immunocytometry Systems) was labeled with Mal/Cy5.5-PerCP by standard means. Briefly, the antibody was derivatized so as to have 6-10 free sulfhydryl moieties per antibody molecule. The reduced antibody was then incubated with a 10 fold excess of Mal/Cy5.5-PerCP, then fractionated by gel filtration on a column containing Superose™

6. The fractions containing antibody conjugated to “buried” Cy5.5-PerCP (CD3-Cy5.5-PerCP) were pooled and used for further studies.

Antibody labeled with the “exposed” Cy5.5 complex of the prior art was synthesized for comparison with the “buried” Cy5.5 complex of the invention. PerCP was derivatized with maleimide groups using succinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC, Pierce Biochemical Corp.) to form PerCP/Mal. PerCP/Mal was then coupled to Cy5.5-mono-OSu (Amersham LifeScience Cat. No. R15600) to form Mal/PerCP-Cy5.5. This complex was used to label CD3 antibody as described above. The resulting labeled antibody conjugate (CD3-PerCP-Cy5.5) leaves
10 the cyanine dye exposed.

Example 2 - Staining of Whole Blood with CD3-Cy5.5-PerCP

Normal human blood (50 μ l) containing EDTA was incubated with 38 ng (10 μ l) CD3-Cy5.5-PerCP (Cy5.5 buried), CD3-PerCP-Cy5.5 (Cy5.5 exposed), or CD3-
15 PerCP (Becton Dickinson Immunocytometry Systems Cat. #347344) for 30 minutes at 25°C. Lysing solution, (1 ml, FACS® Lysing Solution (Becton Dickinson Immunocytometry Systems Cat. No. 349202) was added and after incubation for 10 minutes at 25°C, the samples were centrifuged (10 minutes at 200 x g). The pellet was resuspended in 0.5 ml phosphate buffered saline (PBS)/0.5% bovine serum albumin
20 (BSA) and analyzed with a FACScan™ type flowcytometer using the manufacturer’s directions.

The results, shown in Figures 2 and 3, demonstrate the superior features of the complexes of the invention. Lymphocytes stained with CD3-Cy5.5-PerCP (Cy5.5 “buried”) were approximately five times brighter than lymphocytes stained with CD3-
25 PerCP. Importantly, fluor-specific binding of monocytes was significantly (ten-fold) lower using CD3-Cy5.5-PerCP (Cy5.5 “buried”) compared with using CD3-PerCP-Cy5.5 (Cy5.5 “exposed”). In addition, the baseline gap between the monocyte peak and lymphocytes stained with CD3-Cy5.5-PerCP (Cy5.5 “buried”) was significantly greater

than when stained with either CD3-PerCP-Cy5.5 (Cy5.5 "exposed") or CD3-PerCP (over 1 log vs 0.1 and 0.9 logs, respectively) demonstrating that different cell populations can be more accurately assessed using the conjugates of the invention.

5 Example 3 - Synthesis of Cy5.5-PerCP employing a homobifunctional chromophore

PerCP (12 mg/ml) in 50 mM Na phosphate, 1mM EDTA pH8.0 was incubated with 1mM 2-iminothiolane (Traut's Reagent, Pierce Biochemical Corp.) for 60 minutes at room temperature. The sulphydryl derivatized PerCP was separated from free iminothiolane and other reaction products by buffer exchange into a buffer containing 50
10 mM MES and 2mM EDTA, pH 6.0, using Sephadex™G-25.

The sulphydryl derivitized PerCP was incubated with a 2 molar excess of Bis-maleimide Cy5.5 (Amersham Life Science) for 60 minutes at room temperature. The PerCP-Cy5.5-maleimide protein dye complex was separated from unreacted dye by
15 buffer exchange into a buffer containing 0.14M Na acetate pH 5.5 using Sephadex G-50. The ratio of Cy5.5 to PerCP was determined by absorption at 280, 478 and 674 nm and found to be 0.4:1.

An antibody specific to T-lymphocytes (CD3 (Leu4) Becton Dickinson
20 Immunocytometry Systems) was labeled with the PerCP-Cy5.5-maleimide complex by standard means. Briefly, the antibody was derivitized so as to have 6-10 free sulphydryl moieties per antibody molecule. The sulphydryl antibody was then incubated with 10 molar excess of PerCP-Cy5.5-maleimide complex and then fractionated by gel filtration on a column containing Superose™ 6. The fractions containing antibody conjugated
25 through Cy5.5 to PerCP were pooled for further studies. The ratio of PerCP to antibody was determined by absorption as described above and found to be 4.2:1 and the ratio of Cy5.5 to PerCP 0.5:1.

Example 4 - Alternate means to prepare bifunctional chromophores

In yet another variation of the chemistry described herein, it is possible to link the chromophore (e.g., Cy5.5) to both the signal enhancing agent (e.g., PerCP) and an antibody through only one end of the chromophore. For example, if a mono-amine version of Cy5.5 is reacted with a compound having one succinimidyl and TWO maleimides (such a molecule is sold by Molecular Biosciences, Boulder CO as succinimidyl-3,5-dimaleimidophenyl benzoate), the succinimidyl moiety reacts with the amine moiety in the chromophore, with the net addition of two maleimide moieties to the chromophore, thereby producing a bifunctionalized chromophore. These could be separately linked to signal enhancing agents and antibodies as described herein, thus mediating the conjugation of a signal enhancing agent to an antibody and effectively burying the chromophore between the signal enhancing agent and the antibody.

While the foregoing has been presented with reference to particular embodiments of the invention, it will be appreciated by those skilled in the art that changes in these embodiments may be made without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims.

That which is claimed is:

1. A detectable compound comprising a heterobifunctionalized chromophore, wherein one functionality on said chromophore is capable of coupling with a signal-enhancing agent or a blocking agent, and the other functionality on said chromophore is capable of coupling with a member of a specific binding pair.
- 5 2. A detectable compound according to claim 1 wherein said chromophore is a fluorescent compound.
3. A detectable compound according to claim 1 wherein said chromophore is a non-fluorescent dye.
4. A detectable compound according to claim 2 wherein said fluorescent
10 compound is a cyanine dye.
5. A detectable compound according to claim 4 wherein said cyanine dye is Cy3, Cy3.5, Cy5, Cy5.5, Cy7 or Cy7.5.
6. A detectable compound according to claim 1 wherein said signal-enhancing agent is capable of participating in fluorescent resonance energy transfer with
15 said heterobifunctional chromophore.
7. A detectable compound according to claim 1 wherein said signal-enhancing agent is a fluorescein, rhodamine, umbelliferone or a lanthanide chelate.
8. A detectable compound according to claim 1 wherein said signal-enhancing agent is a phycobiliprotein, a peridinin-chlorophyll-protein complex, a yellow
20 fluorescent protein or a green fluorescent protein.
9. A detectable compound according to claim 1 wherein said signal-enhancing agent is a phycobiliprotein selected from PE or APC.

10. A detectable compound according to claim 1 wherein said signal-enhancing agent is a peridinin-chlorophyll-protein complex.
11. A detectable compound according to claim 1 wherein said blocking agent is capable of reducing the ability of said chromophore to participate in
5 chromophore-specific or non-specific binding.
12. A detectable compound according to claim 1 wherein said blocking agent is a protein, a peptide, an oligonucleotide or a carbohydrate.
13. A detectable compound according to claim 1 wherein said chromophore couples with said signal-enhancing agent or said blocking agent by
10 covalent means.
14. A detectable compound according to claim 1 wherein said member of a specific binding pair is an antibody, an antigen, an oligonucleotide, avidin, streptavidin, or a ligand.
15. A detectable compound according to claim 1 wherein said
15 chromophore couples with said member of a specific binding pair by covalent means.
16. A detectable complex comprising a detectable compound according to claim 1, in combination with a signal-enhancing agent.
17. A detectable complex according to claim 16, further comprising a member of a specific binding pair.
- 20 18. A detectable complex comprising a detectable compound according to claim 1, in combination with a blocking agent.
19. A detectable complex according to claim 18, further comprising a member of a specific binding pair.
- 25 20. A detectable complex comprising a detectable compound according to claim 1, in combination with a member of a specific binding pair.

21. A detectable complex comprising a bifunctionalized chromophore, wherein one functionality on said chromophore is coupled with a signal-enhancing agent or a blocking agent, and the other functionality on said chromophore is coupled with a member of a specific binding pair.

5 22. A detectable complex according to claim 21 wherein said chromophore is a fluorescent compound.

23. A detectable complex according to claim 21 wherein said chromophore is a non-fluorescent dye.

24. A detectable complex according to claim 22 wherein said fluorescent
10 compound is a cyanine dye.

25. A detectable complex according to claim 24 wherein said cyanine dye is Cy3, Cy3.5, Cy5, Cy5.5, Cy7 or Cy7.5.

26. A detectable complex according to claim 21 wherein said signal-enhancing agent is capable of participating in fluorescent resonance energy transfer with
15 said heterobifunctional chromophore.

27. A detectable complex according to claim 21 wherein said signal-enhancing agent is a fluorescein, rhodamine, umbelliferone or a lanthanide chelate.

28. A detectable complex according to claim 21 wherein said signal-enhancing agent is a phycobiliprotein, a peridinin-chlorophyll-protein complex, a yellow
20 fluorescent protein or a green fluorescent protein.

29. A detectable complex according to claim 21 wherein said signal-enhancing agent is a phycobiliprotein selected from PE or APC.

30. A detectable complex according to claim 21 wherein said signal-enhancing agent is a peridinin-chlorophyll-protein complex.

31. A detectable complex according to claim 21 wherein said blocking agent is capable of reducing the ability of said chromophore to participate in chromophore-specific or non-specific binding.

32. A detectable complex according to claim 21 wherein said blocking
5 agent is a protein, a peptide, an oligonucleotide or a carbohydrate.

33. A detectable complex according to claim 21 wherein said chromophore couples with said signal-enhancing agent or said blocking agent by covalent means.

34. A detectable complex according to claim 21 wherein said member of
10 a specific binding pair is an antibody, an antigen, an oligonucleotide, avidin, streptavidin, or a ligand.

35. A detectable complex according to claim 21 wherein said chromophore couples with said member of a specific binding pair by covalent means.

36. A method for the preparation of a detectable compound according to
15 claim 1, said method comprising derivatizing a chromophore with two different reactive groups.

37. A method for the preparation of a detectable complex according to claim 16, said method comprising coupling one of the functional groups on said heterobifunctionalized chromophore with a reactive moiety on a signal-enhancing agent.
20

38. A method for the preparation of a detectable complex according to claim 17, said method comprising coupling one of the functional groups on said heterobifunctionalized chromophore with a reactive moiety on a signal-enhancing agent, and coupling the other functional group on said heterobifunctionalized chromophore with
25 a reactive moiety on a member of a specific binding pair.

39. A method for the preparation of a detectable complex according to claim 18, said method comprising coupling one of the functional groups on said heterobifunctionalized chromophore with a reactive moiety on a blocking agent.

40. A method for the preparation of a detectable complex according to claim 19, said method comprising coupling one of the functional groups on said heterobifunctionalized chromophore with a reactive moiety on a blocking agent, and coupling the other functional group on said heterobifunctionalized chromophore with a reactive moiety on a member of a specific binding pair.

41. A method for the preparation of a detectable complex according to claim 20, said method comprising coupling one of the functional groups on said heterobifunctionalized chromophore with a reactive moiety on a member of a specific binding pair.

42. A method for the preparation of a detectable complex according to claim 21, said method comprising coupling one of the functional groups on a bifunctionalized chromophore with a reactive moiety on a signal-enhancing agent or a blocking agent, and coupling the other functional group on said bifunctionalized chromophore with a reactive moiety on a member of a specific binding pair.

43. In an assay employing as a reagent a fluorescent compound conjugated to a member of a specific binding pair, wherein said pair comprises two biochemical molecules that bind specifically to each other and said assay comprises a step in which the conjugated member of the specific binding pair binds to the other member of the specific binding pair, the improvement comprising employing, as said fluorescent compound, a detectable compound comprising a bifunctionalized chromophore, wherein one functionality on said chromophore is capable of coupling with a signal-enhancing agent or a blocking agent, and the other functionality on said chromophore is capable of coupling with a member of a specific binding pair.


44. A method for reducing chromophore-mediated undesirable binding, said method comprising:

a) reacting a bifunctionalized chromophore with a signal-enhancing agent or blocking agent to form a complex; and


5 b) reacting the complex with a member of a binding pair such that the chromophore is bound between the member of the binding pair and the signal-enhancing agent or blocking agent.

FIG.1

INVENTION



PRIOR ART



— - Cross-Linker

○ - Cy5.5

○ - PerCP

FIG.2C




FIG.2B





FIG.2A



SIDE SCATTER

FIG.3C-1




FIG.3B-1





FIG.3A-1



SIDE SCATTER

FL3-HEIGHT




FIG. 3A-2

FIG. 3B-2

FIG. 3C-2

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/20831

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 G01N33/532 G01N33/533 G01N33/58

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	US 5 714 386 A (ROEDERER MARIO) 3 February 1998 see the whole document ---	1-44
P, X	EP 0 800 083 A (MATSUSHITA ELECTRIC IND CO LTD) 8 October 1997	1, 2, 4, 6, 11, 13, 15, 36, 43
P, Y	see the whole document	5, 7-10, 12, 14, 16-22, 24-35, 37-42, 44
X	US 5 171 846 A (GUPTA RAVINDER K) 15 December 1992 see claims --- -/--	1-44

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 February 1999

Date of mailing of the international search report

08/03/1999

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

 Routledge, B

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No PCT/US 98/20831

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
US 5714386	A	03-02-1998	NONE	
EP 0800083	A	08-10-1997	JP 9325147 A	16-12-1997
US 5171846	A	15-12-1992	EP 0602032 A	22-06-1994
			WO 9303062 A	18-02-1993
			US 5783673 A	21-07-1998
			US 5272257 A	21-12-1993
US 5145772	A	08-09-1992	DE 3788203 D	23-12-1993
			DE 3788203 T	31-03-1994
			EP 0275260 A	27-07-1988
			JP 2506396 B	12-06-1996
			JP 4500901 T	20-02-1992
			WO 8800695 A	28-01-1988
			US 4931223 A	05-06-1990
			US 5605795 A	25-02-1997
			US 5220005 A	15-06-1993
			US 5866389 A	02-02-1999
			US 5869705 A	09-02-1999
			US 5637747 A	10-06-1997
US 5639907 A	17-06-1997			
US 4981977	A	01-01-1991	NONE	